Which PASI Outcome Is Most Relevant to the Patients in Real-World Care?
暂无分享,去创建一个
[1] Muhammad Usman Rathore,et al. Dermatology Life Quality Index In Patients Of Psoriasis And Its Correlation With Severity Of Disease. , 2020, Journal of Ayub Medical College, Abbottabad : JAMC.
[2] P. Tounian,et al. Psoriasis and metabolic and cardiovascular comorbidities in children: A systematic review. , 2019, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.
[3] L. Naldi,et al. Clinical use of dimethyl fumarate in moderate‐to‐severe plaque‐type psoriasis: a European expert consensus , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.
[4] E. H. Thompson,et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials , 2018, The Lancet.
[5] A. Kimball,et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials , 2017, The Lancet.
[6] S. Langan,et al. Psoriasis and comorbid diseases: Epidemiology. , 2017, Journal of the American Academy of Dermatology.
[7] A. Finlay,et al. A systematic review of the use of quality‐of‐life instruments in randomized controlled trials for psoriasis , 2017, The British journal of dermatology.
[8] A. Egeberg. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. , 2016, The New England journal of medicine.
[9] M. D'Angelica,et al. Outcomes of the Memorial Sloan Kettering Cancer Center International General Surgical Oncology Fellowship. , 2016, Journal of the American College of Surgeons.
[10] J. Ortonne,et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. , 2015, Journal of the American Academy of Dermatology.
[11] E. Derviş,et al. The relationship between quality of life and the severity of psoriasis in Turkey , 2015, European Journal of Dermatology.
[12] L. Puig,et al. PASI90 response: the new standard in therapeutic efficacy for psoriasis , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.
[13] A. Kimball,et al. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.
[14] T. Nijsten,et al. Measurement of health‐related quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.
[15] L. Miot,et al. Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment* , 2013, Anais brasileiros de dermatologia.
[16] A. García‐Díez,et al. Comparison of Skindex‐29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis , 2012, The British journal of dermatology.
[17] U. Mrowietz,et al. Implementing treatment goals for successful long‐term management of psoriasis , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.
[18] M. Augustin,et al. Characterization of Patient-Reported Outcomes in Moderate to Severe Psoriasis , 2011, Dermatology.
[19] L. McLeod,et al. Interpreting patient-reported outcome results: US FDA guidance and emerging methods , 2011, Expert review of pharmacoeconomics & outcomes research.
[20] F. Aubin,et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.
[21] K. Reich,et al. Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany , 2008, Dermatology.
[22] T. Nijsten,et al. Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients. , 2007, The Journal of investigative dermatology.
[23] A. Finlay,et al. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.
[24] L. Naldi,et al. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies. , 2010, Clinics in dermatology.
[25] M. Augustin,et al. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. , 2010, European journal of dermatology : EJD.
[26] G. Jensen,et al. Assessment and management , 1998 .
[27] T Fredriksson,et al. Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.